

COVID-19 Vaccine Breakthrough Infections Reported to 1â€“April 30, 2021

Morbidity and Mortality Weekly Report

70, 792-793

DOI: [10.15585/mmwr.mm7021e3](https://doi.org/10.15585/mmwr.mm7021e3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccines & pandemic. Indian Journal of Medical Research, 2021, 153, 517.	0.4	5
2	Post-Vaccination Symptomatic SARS-CoV-2 Infections are Minimal and Non-Serious: An Observational Multicenter Indian Cohort Study of 28342 Healthcare Workers. SSRN Electronic Journal, 0, , .	0.4	2
5	Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil. Viruses, 2021, 13, 1237.	1.5	23
6	What is always necessary throughout efforts to prevent and control COVID-19 and other infectious diseases? A physical containment strategy and public mobilization and management. BioScience Trends, 2021, 15, 188-191.	1.1	6
7	The Great Unmasking of 2021. Journal of Nursing Scholarship, 2021, 53, 391-392.	1.1	0
8	Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State. Clinical Infectious Diseases, 2022, 74, 1089-1092.	2.9	38
18	Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. Vaccines, 2021, 9, 781.	2.1	28
19	Antibodies, boosters, and optimizing SARS-CoV-2 vaccines for transplantation: A call for more research. American Journal of Transplantation, 2022, 22, 24-27.	2.6	8
21	Assessment of Machine Learning Techniques in IoT-Based Architecture for the Monitoring and Prediction of COVID-19. Electronics (Switzerland), 2021, 10, 1834.	1.8	13
23	Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. Transplantation, 2021, 105, e265-e266.	0.5	136
27	Breakthrough COVID-19 Infections After mRNA Vaccination in Solid Organ Transplant Recipients in Miami, Florida. Transplantation, 2021, 105, e139-e141.	0.5	32
30	Sex Differences in Immunity to Viral Infections. Frontiers in Immunology, 2021, 12, 720952.	2.2	123
31	SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status – Los Angeles County, California, May 1 – July 25, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1170-1176.	9.0	107
35	Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021. Annals of Internal Medicine, 2021, 174, 1563-1571.	2.0	23
37	Vaccine Hesitancy towards COVID-19 Vaccination: Investigating the Role of Information Sources through a Mediation Analysis. Infectious Disease Reports, 2021, 13, 712-723.	1.5	40
40	Suspected Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Reinfections: Incidence, Predictors, and Healthcare Use Among Patients at 238 US Healthcare Facilities, 1 June 2020 to 28 February 2021. Clinical Infectious Diseases, 2022, 74, 1489-1492.	2.9	24
41	SARS-CoV-2 Variants. Infectious Diseases & Immunity, 2021, Publish Ahead of Print, .	0.2	1
43	Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 289-291.	0.5	69

#	ARTICLE	IF	CITATIONS
45	Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 868.	3.8	83
47	IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population. <i>Vaccines</i> , 2021, 9, 999.	2.1	23
49	New-Onset Insulin Allergy After COVID-19 Infection in an Insulin-Dependent Type-2 Diabetic Patient: A Rare Complication. <i>Cureus</i> , 2021, 13, e17879.	0.2	0
51	Clinical Outcomes of Adult Patients Hospitalized with COVID-19 after Vaccination. <i>Tropical Medicine and Infectious Disease</i> , 2021, 6, 175.	0.9	10
52	Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients. <i>Viruses</i> , 2021, 13, 1743.	1.5	15
53	Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India. <i>Viruses</i> , 2021, 13, 1782.	1.5	70
54	Silent SARS-CoV-2 Infections, Waning Immunity, Serology Testing, and COVID-19 Vaccination: A Perspective. <i>Frontiers in Immunology</i> , 2021, 12, 730404.	2.2	2
56	Addressing the "hypoxia paradox"™ in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues. <i>Molecular Medicine</i> , 2021, 27, 120.	1.9	9
57	Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case. <i>International Journal of Infectious Diseases</i> , 2021, 110, 232-234.	1.5	21
58	Elucidating causes of COVID-19 infection and related deaths after vaccination. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102212.	1.8	27
60	Factors associated with decision making on COVID-19 vaccine acceptance among college students in South Carolina. <i>Psychology, Health and Medicine</i> , 2022, 27, 150-161.	1.3	38
61	Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	44
63	Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences. <i>American Journal of Pathology</i> , 2021, 191, 1754-1773.	1.9	26
64	Assessment of Simulated Surveillance Testing and Quarantine in a SARS-CoV-2 "Vaccinated Population of Students on a University Campus. <i>JAMA Health Forum</i> , 2021, 2, e213035.	1.0	4
65	Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 2673-2676.	2.0	40
66	Surveillance genome sequencing reveals multiple SARS-CoV-2 variants circulating in central Texas, USA, with a predominance of delta variant and review of vaccine breakthrough cases. <i>Journal of Medical Virology</i> , 2022, 94, 937-944.	2.5	3
69	Analysis of a COVID-19 Prescreening Process in an Outpatient Clinic at a University Hospital during the COVID-19 Pandemic. <i>Journal of Korean Medical Science</i> , 2021, 36, e295.	1.1	1
70	The short-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines among healthcare workers: a systematic literature review and meta-analysis. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2021, 1, .	0.2	4

#	ARTICLE	IF	CITATIONS
71	Increased risk for <scp>COVID</scp>â€19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry, 2022, 21, 124-132.	4.8	105
72	Breakthrough SARSâ€CoVâ€2 infections among BBVâ€152 (COVAXINÂ®) and AZD1222 (COVISHIELDTM) recipients: Report from the eastern state of India. Journal of Medical Virology, 2022, 94, 1201-1205.	2.5	19
73	Actions and attitudes on the immunized patients against SARS-CoV-2. Revista Espanola De Quimioterapia, 2021, , .	0.5	3
74	Update on Coronavirus 2019 Vaccine Guidelines for Transplant Recipients. Transplantation Proceedings, 2022, 54, 1399-1404.	0.3	16
76	COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis. Nutrients, 2021, 13, 3596.	1.7	60
78	SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19. Nature Immunology, 2021, 22, 1452-1464.	7.0	37
82	SARSâ€CoVâ€2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVIDâ€19 Vaccination. Hepatology Communications, 2022, 6, 889-897.	2.0	36
83	Disparities In County COVID-19 Vaccination Rates Linked To Disadvantage And Hesitancy. Health Affairs, 2021, 40, 1792-1796.	2.5	22
84	COVID Vaccination in Athletes and Updated Interim Guidance on the Preparticipation Physical Examination During the SARS-Cov-2 Pandemic. Clinical Journal of Sport Medicine, 2022, 32, e1-e6.	0.9	10
85	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. Medicinski Podmladak, 2021, 72, 20-29.	0.2	3
86	COVID-19 Vaccines: A weapon for global security. APIK Journal of Internal Medicine, 2021, 9, 200.	0.1	0
88	Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections. Frontiers in Immunology, 2021, 12, 742167.	2.2	32
89	COVID19 â€Far from Over: Call for Urgent Novel and Advanced Measures. Coronaviruses, 2021, 02, .	0.2	0
90	SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science, 2022, 375, 331-336.	6.0	202
91	Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. Journal of Clinical Virology, 2021, 145, 105026.	1.6	29
92	Reinfection and Breakthrough Infection of SARS-CoV-2: An Emerging Challenge That Is Threatening Our World. Infectious Diseases & Immunity, 2022, 2, 29-33.	0.2	3
93	Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA - Journal of the American Medical Association, 2021, 326, 2043.	3.8	458
94	Coronavirus Disease 2019 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida Through August 2021. Clinical Infectious Diseases, 2022, 75, e892-e894.	2.9	25

#	ARTICLE	IF	CITATIONS
95	Transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2), delta variant, between two fully vaccinated healthcare personnel. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1983-1985.	1.0	1
96	In-depth Characterization of Vaccine Breakthrough Infections With SARS-CoV-2 Among Health Care Workers in a Dutch Academic Medical Center. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab553.	0.4	4
98	COVID-19: stigmatising the unvaccinated is not justified. <i>Lancet</i> , The, 2021, 398, 1871.	6.3	25
100	Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India. <i>Journal of Medical Virology</i> , 2022, 94, 1696-1700.	2.5	20
101	When Do We Need Massive Computations to Perform Detailed COVID-19 Simulations?. <i>Advanced Theory and Simulations</i> , 2022, 5, 2100343.	1.3	8
102	Licorice (<i>Glycyrrhiza glabra</i>) Extracts-Suitable Pharmacological Interventions for COVID-19? A Review. <i>Plants</i> , 2021, 10, 2600.	1.6	13
104	Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2. <i>FEBS Open Bio</i> , 2022, 12, 285-294.	1.0	20
105	Accounting for Pandemic: Better Numbers for Management and Policy. <i>Accounting, Economics and Law: A Convivium</i> , 2021, 11, 277-291.	0.6	1
106	Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease. <i>Cells</i> , 2021, 10, 3367.	1.8	42
107	Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study. <i>Microbiology Spectrum</i> , 2021, 9, e0188221.	1.2	5
109	COVID Vaccination in Athletes & Updated Interim Guidance on the Preparticipation Physical Examination during the SARS-CoV-2 Pandemic. <i>Current Sports Medicine Reports</i> , 2021, 20, 608-613.	0.5	6
110	Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas. <i>American Journal of Pathology</i> , 2022, 192, 320-331.	1.9	90
111	At-home testing to mitigate community transmission of SARS-CoV-2: protocol for a public health intervention with a nested prospective cohort study. <i>BMC Public Health</i> , 2021, 21, 2209.	1.2	17
112	Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. <i>Lancet Microbe</i> , The, 2022, 3, e4-e5.	3.4	45
113	The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. <i>Journal of Functional Foods</i> , 2021, 87, 104850.	1.6	23
114	Should Breakthrough SARS-CoV-2 Infection Affect Our Confidence in the COVID-19 Vaccines?. <i>Infection and Chemotherapy</i> , 2021, 53, 676.	1.0	7
115	Transmission and containment of the SARS-CoV-2 Delta variant of concern in Guangzhou, China: A population-based study. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010048.	1.3	25
117	Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. <i>Nature Microbiology</i> , 2022, 7, 277-288.	5.9	37

#	ARTICLE	IF	CITATIONS
118	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. <i>Nature Communications</i> , 2022, 13, 532.	5.8	53
119	Impact of COVID-19 on healthcare waste generation: Correlations and trends from a tertiary hospital of a developed country. <i>Waste Management and Research</i> , 2022, 40, 1450-1457.	2.2	3
121	Clinical characteristics of COVID-19 in solid organ transplant recipients following COVID-19 vaccination: A multicenter case series. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	16
122	Potential Genes Associated with COVID-19 and Comorbidity. <i>International Journal of Medical Sciences</i> , 2022, 19, 402-415.	1.1	26
123	A Retrospective Cross-Sectional Study of Severe Breakthrough SARS-CoV-2 Infection in the General Population Requiring Hospitalization Within a Single Health System. <i>Journal of Clinical Medicine Research</i> , 2022, 14, 45-52.	0.6	1
124	COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research. <i>Blood Reviews</i> , 2022, 54, 100931.	2.8	49
125	Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 734279.	2.2	5
126	Comorbidities and Vaccination Status of COVID-19 All-Cause Mortality at a Tertiary Care Center of Western India. <i>Cureus</i> , 2022, 14, e21721.	0.2	4
127	Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. <i>EBioMedicine</i> , 2022, 75, 103762.	2.7	32
128	B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses. <i>Emerging Microbes and Infections</i> , 2022, 11, 452-464.	3.0	8
129	SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhône District, Southern France, 2021. <i>Frontiers in Microbiology</i> , 2021, 12, 796807.	1.5	5
131	Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021. <i>Frontiers in Medicine</i> , 2021, 8, 815870.	1.2	8
132	Statistical estimation of deltoid subcutaneous fat pad thickness: implications for needle length for vaccination. <i>Scientific Reports</i> , 2022, 12, 1069.	1.6	5
133	COVID-19 reinfections among naturally infected and vaccinated individuals. <i>Scientific Reports</i> , 2022, 12, 1438.	1.6	79
134	Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis. <i>Hepatology</i> , 2022, 76, 126-138.	3.6	49
136	Sexual dimorphism in COVID-19: potential clinical and public health implications. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 221-230.	5.5	78
137	Prevalence of Antibodies to SARS-CoV-2 Following Natural Infection and Vaccination in Irish Hospital Healthcare Workers: Changing Epidemiology as the Pandemic Progresses. <i>Frontiers in Medicine</i> , 2021, 8, 758118.	1.2	15
138	Molecular accuracy vs antigenic speed: SARS-CoV-2 testing strategies. <i>Current Opinion in Pharmacology</i> , 2022, 62, 152-158.	1.7	3

#	ARTICLE	IF	CITATIONS
139	SARS-CoV-2 Vaccine in Dialysis Patients: Time for a Boost?. American Journal of Kidney Diseases, 2022, 79, 162-163.	2.1	5
140	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. JCI Insight, 2022, 7, .	2.3	12
141	Hospitalized patients with breakthrough COVID-19: Clinical features and poor outcome predictors. International Journal of Infectious Diseases, 2022, 118, 89-94.	1.5	15
142	Incidence and severity of COVID-19 infection post-vaccination: a survey among Indian doctors. Infection, 2022, 50, 889-895.	2.3	6
143	Factors associated with SARS-CoV-2 antibody titers and prognosis of breakthrough infection in hemodialysis patients. Clinical and Experimental Nephrology, 2022, 26, 571-580.	0.7	13
144	Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. JAMA Internal Medicine, 2022, 182, 153.	2.6	182
145	The Future Disease Burden of Pandemic Covid-19 for Individuals, Communities, and Society. Environmental Claims Journal, 0, , 1-15.	0.5	0
148	Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opinion on Investigational Drugs, 2022, 31, 41-58.	1.9	26
149	Worker Response to the Rapid Changes Caused by Disruptive Innovation. Advances in Human Resources Management and Organizational Development Book Series, 2022, , 189-205.	0.2	3
150	Clinico-Demographic Profile of Vaccinated/Partially Vaccinated Versus Non-Vaccinated Covid-19 Cases in Second Wave of India. Journal of Evolution of Medical and Dental Sciences, 2022, 11, 120-125.	0.1	1
151	Multiple COVID-19 Waves and Vaccination Effectiveness in the United States. International Journal of Environmental Research and Public Health, 2022, 19, 2282.	1.2	36
153	Large-Scale Implementation of a Daily Rapid Antigen Testing Program in California for Detecting SARS-CoV-2. American Journal of Public Health, 2022, 112, 467-471.	1.5	2
154	Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations?. Frontiers in Microbiology, 2022, 13, 763169.	1.5	3
155	Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral) Tj ETQq1 1 0.784314 rgBT /Over the healthcare workers. Infection Control and Hospital Epidemiology, 2023, 44, 75-81.	1.0	9
156	Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. Stem Cell Research and Therapy, 2022, 13, 112.	2.4	14
157	SARS-CoV-2 variants, immune escape, and countermeasures. Frontiers of Medicine, 2022, 16, 196-207.	1.5	39
158	Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India. Human Vaccines and Immunotherapeutics, 2022, 18, 1-7.	1.4	27
159	Severe Acute Respiratory Syndrome Coronavirus 2 Delta Vaccine Breakthrough Transmissibility in Alachua County, Florida. Clinical Infectious Diseases, 2022, 75, 1618-1627.	2.9	4

#	ARTICLE	IF	CITATIONS
160	Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. <i>International Journal of Infectious Diseases</i> , 2022, 119, 87-94.	1.5	35
161	A Review: The Manifestations, Mechanisms, and Treatments of Musculoskeletal Pain in Patients With COVID-19. <i>Frontiers in Pain Research</i> , 2022, 3, 826160.	0.9	13
162	Low-frequency variants in mildly symptomatic vaccine breakthrough infections presents a double-edged sword. <i>Journal of Medical Virology</i> , 2022, , .	2.5	8
163	Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. <i>Clinical Microbiology and Infection</i> , 2022, 28, 596-601.	2.8	3
165	Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. <i>Nature Medicine</i> , 2022, 28, 1491-1500.	15.2	239
166	The effect of pandemic prevalence on the reported efficacy of SARS-CoV-2 vaccines. <i>PLoS ONE</i> , 2022, 17, e0266271.	1.1	0
167	Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021. <i>JAMA Oncology</i> , 2022, 8, 1027.	3.4	61
168	Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021. <i>Journal of Infection</i> , 2022, 85, e26-e29.	1.7	2
169	Improved SARS-CoV-2 main protease high-throughput screening assay using a 5-carboxyfluorescein substrate. <i>Journal of Biological Chemistry</i> , 2022, 298, 101739.	1.6	16
170	SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study. <i>International Journal of Infectious Diseases</i> , 2022, 118, 95-103.	1.5	24
171	Clinical characterization of COVID-19 breakthrough infections, Philippines. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105157.	1.6	3
172	The pH Dependence of Niclosamide Solubility, Dissolution, and Morphology: Motivation for Potentially Universal Mucin-Penetrating Nasal and Throat Sprays for COVID19, its Variants and other Viral Infections. <i>Pharmaceutical Research</i> , 2022, 39, 115-141.	1.7	11
173	Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers. <i>Vaccines</i> , 2022, 10, 54.	2.1	8
175	COVID-19 Vaccine Hesitancy Among the Adult Population in Saudi Arabia. <i>Cureus</i> , 2021, 13, e20197.	0.2	6
176	Modeling the Influence of Vaccine Administration on COVID-19 Testing Strategies. <i>Viruses</i> , 2021, 13, 2546.	1.5	7
177	COVID-19 Positive Testing in Minnesota High School Fall and Winter Sports. <i>Clinical Journal of Sport Medicine</i> , 2021, Publish Ahead of Print, 283-289.	0.9	1
179	Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5133-5134.	1.4	0
181	COVID-19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021. <i>Alzheimer's and Dementia</i> , 2023, 19, 421-432.	0.4	26

#	ARTICLE	IF	CITATIONS
185	Recurrent neural network models (CovRNN) for predicting outcomes of patients with COVID-19 on admission to hospital: model development and validation using electronic health record data. The Lancet Digital Health, 2022, 4, e415-e425.	5.9	35
186	SARS-CoV-2 Breakthrough Infections among US Embassy Staff Members, Uganda, May-June 2021. Emerging Infectious Diseases, 2022, 28, .	2.0	4
187	To Boost or Not to Boost: Acceptability of a COVID-19 Booster Dose among Osteopathic Medical Students: A Cross-Sectional Study from a Medical School in New York. Epidemiologia, 2022, 3, 218-228.	1.1	2
188	POST VACCINATION COVID POSITIVE INPATIENTS IN A TERTIARY CARE HOSPITAL – AN ANALYSIS. , 2022, , 50-52.		0
189	An adaptive, asymptomatic SARS-CoV-2 workforce screening program providing real-time, actionable monitoring of the COVID-19 pandemic. PLoS ONE, 2022, 17, e0268237.	1.1	3
190	What is the Hidden Biological Mechanism Underlying the Possible SARS-CoV-2 Vertical Transmission? A Mini Review. Frontiers in Physiology, 2022, 13, .	1.3	6
191	Alpha, Beta, Delta, Omicron, and SARS-CoV-2 Breakthrough Cases: Defining Immunological Mechanisms for Vaccine Waning and Vaccine-Variant Mismatch. Frontiers in Virology, 2022, 2, .	0.7	14
192	At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers. BMC Infectious Diseases, 2022, 22, 443.	1.3	4
193	Trends and Correlates of Breakthrough Infections With SARS-CoV-2. Frontiers in Public Health, 2022, 10, .	1.3	5
194	Adults hospitalized with breakthrough COVID-19 have lower mortality than matched unvaccinated adults. Journal of Internal Medicine, 2022, 292, 377-384.	2.7	8
195	Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic. Vaccines, 2022, 10, 755.	2.1	13
196	Clinical profile of post-vaccination COVID-19-positive patients. , 2021, 9, 107.		0
197	Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis. JMIR Public Health and Surveillance, 2022, 8, e35311.	1.2	13
198	Breakthrough Infections of COVID-19 among Vaccinated Healthcare Workers in a Tertiary Care Hospital in Northern Kerala, India. Journal of Pure and Applied Microbiology, 0, , .	0.3	0
199	Human Identical Sequences, hyaluronan, and hymecromone – the new mechanism and management of COVID-19. Molecular Biomedicine, 2022, 3, 15.	1.7	4
200	The impact of COVID-19 vaccination on California's return to normalcy. PLoS ONE, 2022, 17, e0264195.	1.1	2
201	COVID-19 Vaccine Breakthrough Infections and Associated Factors in Kwekwe City, Zimbabwe, 2021. Open Journal of Epidemiology, 2022, 12, 170-184.	0.2	0
202	Synthesis and Biochemical Evaluation of 8H-Indeno[1,2-d]thiazole Derivatives as Novel SARS-CoV-2 3CL Protease Inhibitors. Molecules, 2022, 27, 3359.	1.7	1

#	ARTICLE	IF	CITATIONS
204	COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents. <i>EBioMedicine</i> , 2022, 80, 104066.	2.7	30
205	Letter to editor about the articles of "Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections" <i>Brain, Behavior, and Immunity</i> , 2022, 104, 216.	2.0	0
206	Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 81.	0.9	15
207	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. <i>Medical Review</i> , 2022, 2, 169-196.	0.3	5
208	Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) Vaccine Booster Dosing in Brazilian Healthcare Workers, 2021. <i>Clinical Infectious Diseases</i> , 2023, 76, e360-e366.	2.9	21
209	Risks of adverse outcomes in COVID-19 patients and vaccination status in a secondary hospital in Spain. <i>Vacunas</i> , 2022, , .	1.1	0
210	Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection. <i>Annals of Medicine and Surgery</i> , 2022, 79, .	0.5	1
211	COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature. <i>Cureus</i> , 2022, , .	0.2	11
212	Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States. <i>JAMA Network Open</i> , 2022, 5, e2215934.	2.8	41
213	A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. <i>Nature Communications</i> , 2022, 13, .	5.8	22
214	Examining the impact of COVID-19 vaccination rates on differential access to critical care. <i>Applied Geography</i> , 2022, 145, 102751.	1.7	1
215	Epidemiological and clinical characteristics of SARS-CoV-2 reinfections in a Spanish region. <i>SAGE Open Medicine</i> , 2022, 10, 205031212211085.	0.7	2
217	Embitterment during the COVID-19 Pandemic in Reaction to Injustice, Humiliation, and Breach of Trust. <i>Psychiatry International</i> , 2022, 3, 206-211.	0.5	2
218	Clinical characteristics and outcome of hospitalized elderly patients with COVID-19 after vaccine failure. <i>Vaccine</i> , 2022, 40, 4307-4311.	1.7	3
219	Assessment of Clinical Profile and Treatment Outcome in Vaccinated and Unvaccinated SARS-CoV-2 Infected Patients. <i>Vaccines</i> , 2022, 10, 1125.	2.1	6
220	The impact of traumatic experiences, coping mechanisms, and workplace benefits on the mental health of U.S. public health workers during the COVID-19 pandemic. <i>Annals of Epidemiology</i> , 2022, 74, 66-74.	0.9	4
221	Clinico-Epidemiological Characteristics of Healthcare Workers with SARS-CoV-2 Infection during the First and Second Waves in a Teaching Hospital from Eastern India: A Comparative Analysis. <i>Hospital Topics</i> , 0, , 1-12.	0.3	0
222	Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. <i>EBioMedicine</i> , 2022, 82, 104141.	2.7	11

#	ARTICLE	IF	CITATIONS
223	Diagnostics of messenger ribonucleic acid (mRNA) severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccination-associated myocarditis – A systematic review. <i>Rechtsmedizin</i> , 0, , .	2.6	1
224	Can disposable masks be worn more than once?. <i>Ecotoxicology and Environmental Safety</i> , 2022, 242, 113908.	2.9	4
225	Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron. <i>Cell Research</i> , 2022, 32, 831-842.	5.7	16
226	Characterization of Clinical Features of Hospitalized Patients Due to the SARS-CoV-2 Infection in the Absence of Comorbidities Regarding the Sex: An Epidemiological Study of the First Year of the Pandemic in Brazil. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8895.	1.2	4
227	Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States Before the Delta- and Omicron-Associated Surges: A Retrospective Cohort Study of Repeat Blood Donors. <i>Journal of Infectious Diseases</i> , 2022, 226, 1556-1561.	1.9	3
228	Breath-holding physiology, radiological severity and adverse outcomes in COVID-19 patients: A prospective validation study. <i>Respirology</i> , 2022, 27, 1073-1082.	1.3	1
229	Breakthrough COVID-19 infection according to the infectious diseases hospital. <i>Kazan Medical Journal</i> , 2022, 103, 541-551.	0.1	1
230	Applying Regressive Machine Learning Techniques in Determination of COVID-19 Vaccinated Patients's Influence on the Number of Confirmed and Deceased Patients. <i>Mathematics</i> , 2022, 10, 2925.	1.1	1
231	COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study. <i>BMJ Open</i> , 2022, 12, e067095.	0.8	1
232	Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19. <i>Virus Research</i> , 2022, 319, 198882.	1.1	10
233	Stability and inactivation of SARS-CoV-2 on food contact surfaces. <i>Food Control</i> , 2023, 143, 109306.	2.8	13
234	Detrimental Effects of COVID-19 Measures on Mental Health and Social-Economic Disparities. <i>International Journal of Mental Health Promotion</i> , 2022, .	0.4	0
235	Clinical profile of ChAdOx1 nCoV-19- and BBV152-vaccinated individuals among hospitalized COVID-19 patients: a pair-matched study. , 2022, 10, 251513552211150.	1.4	0
236	Profile of Brazilian inpatients with COVID-19 vaccine breakthrough infection and risk factors for unfavorable outcome. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 0, , 1-10.	0.6	3
237	College openings in the United States increase mobility and COVID-19 incidence. <i>PLoS ONE</i> , 2022, 17, e0272820.	1.1	13
238	Prognosis of COVID-19 in the middle eastern population, knowns and unknowns. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
239	Parents' perception of COVID-19 risk of infection and intention to vaccinate their children. <i>Vacunas</i> , 2023, 24, 37-44.	1.1	2
240	Association of mortality and early tracheostomy in patients with COVID-19: a retrospective analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	4

#	ARTICLE	IF	CITATIONS
241	Rate of True-Positive Findings of COVID-19 Typical Appearance at Chest CT per RSNA Consensus Guidelines in an Increasingly Vaccinated Population. <i>Radiology</i> , 2023, 306, .	3.6	7
242	COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness. <i>Infection and Drug Resistance</i> , 0, Volume 15, 5167-5182.	1.1	9
243	Effectiveness and safety of COVID-19 vaccines in patients with diabetes as a factor for vaccine hesitancy. <i>World Journal of Diabetes</i> , 2022, 13, 738-751.	1.3	8
244	SARS-CoV-2 Infections Among Vaccinated Patients on Maintenance Dialysis, January 1-August 31, 2021, United States. <i>Kidney360</i> , 0, 3, 10.34067/KID.0003092022.	0.9	0
245	Assessment of SARS-CoV-2 vaccination status in SARS-COV-2 infected patients admitted in DrÂRuth K.M. Pfau, Civil Hospital Karachi. <i>Pakistan Journal of Medical Sciences</i> , 2022, 38, .	0.3	0
246	Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, Januaryâ€“March 2021. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	0
247	Estimate of undetected severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in acute-care hospital settings using an individual-based microsimulation model. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 898-907.	1.0	1
248	Coronavirus disease 2019 (COVID-19) vaccine breakthrough infections among healthcare personnel, December 2020â€“April 2021. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2022, 2, .	0.2	0
249	A Literature Survey on Vaccine Supply Chain Management Amidst COVID-19: Literature Developments, Future Directions and Open Challenges for Public Health. <i>World</i> , 2022, 3, 876-903.	1.0	4
250	No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers. <i>Journal of Infection</i> , 2022, 85, e177-e180.	1.7	6
251	The effects of the COVID-19 pandemic on the mental health of workers and the associated social-economic aspects: A narrative review. <i>Work</i> , 2023, 74, 31-45.	0.6	5
252	Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review. <i>Infection</i> , 2023, 51, 285-303.	2.3	1
253	Effect on the conformations of the spike protein of SARSâ€“CoVâ€“2 due to mutation. <i>Biotechnology and Applied Biochemistry</i> , 2023, 70, 979-991.	1.4	2
254	COVID-19 Infection after vaccination among Healthcare Workers at a Tertiary Level Health Care Center in Northern India: A Cross-Sectional Study. <i>Recent Advances in Anti-Infective Drug Discovery</i> , 2022, 17, .	0.4	0
255	Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. <i>JAMA Network Open</i> , 2022, 5, e2236397.	2.8	19
256	The Effect of a Booster Dose mRNA Vaccine on COVID-19 Infection in Kidney Transplant Recipients after Inactivated or Viral Vector Vaccine Immunization. <i>Vaccines</i> , 2022, 10, 1690.	2.1	2
257	Modified susceptibleâ€“exposedâ€“infectiousâ€“recovered model for assessing the effectiveness of non-pharmaceutical interventions during the COVID-19 pandemic in Seoul. <i>Journal of Theoretical Biology</i> , 2023, 557, 111329.	0.8	4
258	Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study. <i>ELife</i> , 0, 11, .	2.8	7

#	ARTICLE	IF	CITATIONS
259	Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant. <i>Vaccines</i> , 2022, 10, 1728.	2.1	5
260	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
261	COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey. <i>Rheumatology International</i> , 2023, 43, 47-58.	1.5	9
262	Hospitalization among vaccines for SARS-CoV-2 breakthrough infection after dose sparing strategies in Libya: A cohort study. <i>PLoS ONE</i> , 2022, 17, e0276425.	1.1	0
263	Likelihood of COVID-19 reinfection in an urban community cohort in Massachusetts. , 2022, 1, 100057.		0
264	Silver and Silver Nanoparticles for the Potential Treatment of COVID-19: A Review. <i>Coatings</i> , 2022, 12, 1679.	1.2	5
265	Adverse effect signature extraction and prediction for drugs treating COVID-19. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
266	Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina. <i>Vaccines</i> , 2022, 10, 1922.	2.1	5
267	Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond. <i>IScience</i> , 2022, 25, 105507.	1.9	10
268	Mathematical model of COVID-19 transmission dynamics incorporating booster vaccine program and environmental contamination. <i>Heliyon</i> , 2022, 8, e11513.	1.4	5
269	COVID-19 Breakthrough Infections in Vaccinated Kidney Transplant Recipients. <i>Vaccines</i> , 2022, 10, 1911.	2.1	1
270	Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy. , 2022, 1, 100074.		2
271	Clinical performance evaluation of BD SARS-CoV-2 reagents for BD MAX TM System in asymptomatic individuals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, , 115861.	0.8	0
272	Evaluation of the Effectiveness of Immunization Saint-Petersburg Population against COVID-19. <i>Epidemiologiya i Vaktsinoprofilaktika</i> , 2022, 21, 21-28.	0.2	1
273	Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination. <i>Journal of Theoretical Biology</i> , 2023, 559, 111384.	0.8	7
274	Risks of adverse outcomes in COVID-19 patients and vaccination status in a secondary hospital in Spain. <i>Vacunas (English Edition)</i> , 2022, 23, S32-S35.	0.3	0
275	Severe acute respiratory syndrome coronavirus 2 vaccine breakthrough infections: A single metro-based testing network experience. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
276	Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review. <i>Medicina (Lithuania)</i> , 2022, 58, 1733.	0.8	2

#	ARTICLE	IF	CITATIONS
277	A COVID-19 model incorporating variants, vaccination, waning immunity, and population behavior. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
278	Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
279	Modeling COVID-19 transmission between age groups in the United States considering virus mutations, vaccinations, and reinfection. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
280	Phase III randomized clinical trial of BV4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2 infections and its impact on inflammatory biomarkers. <i>Phytotherapy Research</i> , 2023, 37, 1232-1241.	2.8	5
281	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
282	Epidemiological characteristics and quarantine assessment of imported international COVID-19 cases, March to December 2020, Chengdu, China. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
283	Real-world effectiveness of COVID-19 vaccination in liver cirrhosis: a systematic review with meta-analysis of 51,834 patients. <i>Baylor University Medical Center Proceedings</i> , 0, , 1-6.	0.2	0
284	The association of demographic and socioeconomic factors with COVID-19 during pre- and post-vaccination periods: A cross-sectional study of Virginia. <i>Medicine (United States)</i> , 2023, 102, e32607.	0.4	0
286	A generalized distributed delay model of COVID-19: An endemic model with immunity waning. <i>Mathematical Biosciences and Engineering</i> , 2023, 20, 5379-5412.	1.0	4
287	Scales, Pseudoscales, the Human Factor, and a Way Forward. , 2023, , 177-224.		0
288	Does COVID-19 Vaccine Impact the Soul? A Pre-post Vaccination Comparison of Health Care Workers' Infection Control Practices and Perspectives. <i>Infectious Diseases in Clinical Practice</i> , 2023, 31, .	0.1	0
289	A Study on The Efficacy of Vaccination in Elderly Patients with Breakthrough COVID-19 Infection. <i>Korean Journal of Clinical Geriatrics</i> , 2022, 23, 115-122.	0.3	0
290	Higher COVID-19 Vaccination Rates Are Associated with Lower COVID-19 Mortality: A Global Analysis. <i>Vaccines</i> , 2023, 11, 74.	2.1	11
291	Cultural and Social Factors in Care Delivery Among African American Caregivers of Persons With Dementia: A Scoping Review. <i>Gerontology and Geriatric Medicine</i> , 2023, 9, 233372142311520.	0.8	1
292	Kinetics of SARS-CoV-2 neutralizing antibodies in Omicron breakthrough cases with inactivated vaccination: Role in inferring the history and duration of infection. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
293	Role of vaccination and anti-SARS-CoV-2 antibodies in the clinical outcome of hospitalized COVID-19 patients. <i>Medicina Clínica</i> , 2023, 160, 476-483.	0.3	8
294	A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New SARS-CoV-2 Variants of Concern. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	1
295	SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 – June 30, 2021. <i>Vaccine</i> , 2023, 41, 1295-1298.	1.7	0

#	ARTICLE	IF	CITATIONS
296	An Overview of Current Accomplishments and Gaps of COVID-19 Vaccine Platforms and Considerations for Next Generation Vaccines. <i>Journal of Pharmaceutical Sciences</i> , 2023, 112, 1345-1350.	1.6	3
297	Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants. <i>Journal of Infectious Diseases</i> , 2023, 227, 1164-1172.	1.9	5
298	Evaluating Policies to Decrease the Risk of Introducing SARS-CoV-2 Infections to Nursing Home Facilities. <i>Journal of Applied Gerontology</i> , 0, , 073346482311558.	1.0	1
299	COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates. <i>Journal of Epidemiology and Global Health</i> , 2023, 13, 67-90.	1.1	3
301	Parents' perception of COVID-19 risk of infection and intention to vaccinate their children. <i>Vacunas (English Edition)</i> , 2023, 24, 37-44.	0.3	0
302	Impact of COVID-19 vaccines on the health status of young female adults from India: A cross-sectional study. <i>Journal of Family Medicine and Primary Care</i> , 2023, 12, 338.	0.3	0
303	Death Reporting in Breakthrough and Unvaccinated SARS-CoV-2 Infection Cases. <i>Disaster Medicine and Public Health Preparedness</i> , 2023, 17, .	0.7	0
304	Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
305	Clinical Characterization and Outcomes of Patients with Hypercreatinemia Affected by COVID-19. <i>Healthcare (Switzerland)</i> , 2023, 11, 944.	1.0	0
306	Coronavirus disease 2019 vaccine in pediatric post-renal transplantation. <i>Clinical Transplantation</i> , 2023, 37, .	0.8	0
307	Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study. <i>Vaccines</i> , 2023, 11, 819.	2.1	0